Enfortumab Vedotina

Resumen

Alternativas con registro en Colombia

• Edrecolomab
• Gemtuzumab Ozogamicina
• Ipilimumab · costo anual estimado $ 1.144.599.485
• Brentuximab Vedotina
• Blinatumomab · costo anual estimado $ 575.343.295
• Polatuzumab Vedotin · costo anual estimado $ 634.694.850
• Sacituzumab Govitecan · costo anual estimado $ 835.929.935
• Tremelimumab
• Tarlatamab

Estudios clínicos principales

• EV-302: Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
  Fase 3 · 2020 · 886 participantes · Astellas Pharma Global Development, Inc. · NCT04223856
• A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
  Fase 3 · 2018 · 608 participantes · Astellas Pharma Global Development, Inc. · NCT03474107
• Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Particip
  Fase 3 · 2019 · 595 participantes · Merck Sharp & Dohme LLC · NCT03924895
• KEYNOTE-B15: Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC)
  Fase 3 · 2021 · 808 participantes · Merck Sharp & Dohme LLC · NCT04700124

Enfermedades relacionadas

• Cáncer (todos)
• Cáncer de vejiga y urotelial

Fuentes

• Etiqueta FDA (DailyMed): PADCEV EJFV
• EMA: Padcev